Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancerRodrigo Sánchez-Bayona, Pablo Tolosa, Mario Martínez-López et al.|Cancer Research|2022Cited by 4
Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancerSantiago Terán, Rodrigo Sánchez-Bayona, Manuel Alva et al.|The Breast|2023Cited by 4
49P Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohortRodrigo Sánchez-Bayona, Eva Ciruelos, Pablo Tolosa et al.|Annals of Oncology|2022Cited by 1
248P Real-world relapse-free survival in HR+/HER2- breast cancer with PAM50 intermediate-risk groupSantiago Terán, Rodrigo Sánchez-Bayona, M. Quevedo et al.|ESMO Open|2025Cited by 0